左西孟旦对急性失代偿性心衰的疗效观察

Efficacy of Levosimendan in Treatment Acute Decompensated Heart Failure

目的评价左西孟旦治疗急性失代偿性心衰的临床疗效。方法将60例急性失代偿性心衰患者随机分为观察组和对照组,每组30例。观察组在常规心力衰竭治疗的基础上加用左西孟旦静脉滴注维持24 h。比较两组治疗前后血浆N末端B型利钠肽前体(NT-pro BNP)、每搏输出量(SV)、左室射血分数(LVEF)、6 min步行距离(6MWD)等心功能指标。结果用药后两组NT-pro BNP、SV、LVEF、6 min步行距离等指标较治疗前均有改善(均P>0.05),且观察组优于对照组[NT-pro BNP(7 246.87±4 349.61)pg·mL^(-1) vs(8 247.56±3 938.52)pg·mL^(-1) ,SV(72.60±5.98)m L vs(68.17±4.92)m L,LVEF(37.27±3.67)%vs(34.93±4.91)%,6 MWD(354.57±31.39)m vs(370.77±21.91)m(均P<0.05)]。结论左西孟旦治疗失代偿性心衰疗效优于常规治疗,值得推广使用。

Objective To evaluate the clinical efficacy of levosimendan in treatment the acute decompensated heart failure. Methods 60 patients with acute decompensated heart failure were randomly divided into levosimendan group and control group(30 cases in each group).Levosimendan group maintained 24 h on the basis of routine heart failure treatment with levosimendan intravenous drip.The plasma N terminal type B natriuretic peptide(NT-proBNP),stroke volume(SV),left ventricular ejection fraction(LVEF),and 6 minute walking distance(6MWD)were compared between two groups before and after treatment. Results After treatment,two groups of NT-proBNP,SV,LVEF and 6MWD were improved(all P>0.05),and levosimendan group than the control group(NT-proBNP(7 246.87±4 349.61)pg·mL-1 vs(8 247.56±3 938.52)pg·mL-1,SV(72.60±5.98)mL vs(68.17±4.92)mL,LVEF(37.27±3.67)%vs(34.93±4.91)%,6 MWD(354.57±31.39)m vs(370.77±21.91)m(all P<0.05). Conclusion Levosimendan was superior to conventional therapy in treatment the decompensated heart failure.